News

NGM Biopharmaceuticals, Inc. a biotechnology company focused on discovering and developing transformative therapeutics for patients, announced the expansion of its oncology portfolio…
Read More...

Akron Biotechnology announced it has signed an agreement with Synairgen plc  for the provision of SNG001, Synairgen’s wholly-owned inhaled interferon beta (IFN-beta) therapeutic…
Read More...

Edesa Biotech, Inc. a clinical-stage biopharmaceutical company, has received clearance from the U.S. Food and Drug Administration (FDA) to begin the Phase 2 portion of its Phase 2/3…
Read More...

Genesis Therapeutics, a privately-held company inventing and deploying state-of-the-art artificial intelligence (AI) techniques to augment drug discovery and development, announced that…
Read More...

AstraZeneca’s Forxiga (dapagliflozin) has been recommended for an indication extension of its marketing authorisation in the European Union (EU) for the treatment of symptomatic chronic…
Read More...

Dr. Reddy’s Laboratories Ltd. and Russian Direct Investment Fund (RDIF), Russia’s sovereign wealth fund,  announced that they have received approval from the Drug Control General of…
Read More...

Orchard Therapeutics, a global gene therapy leader, today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a…
Read More...

ImmunityBio, Inc., a privately-held immunotherapy company, announced it has received authorization from the U.S. Food and Drug Administration (FDA) to begin a Phase I clinical trial of…
Read More...

Merck, known as MSD outside the United States and Canada, announced that the U.S. Food and Drug Administration (FDA) has approved an expanded label for KEYTRUDA, Merck’s anti-PD-1…
Read More...

Sanofi Pasteur, the vaccines global business unit of Sanofi, and Translate Bio, a clinical-stage messenger RNA (mRNA) therapeutics company, today announced the preclinical results for…
Read More...

Allogene Therapeutics, Inc. a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) therapies for cancer, and The University of Texas MD…
Read More...

Eli Lilly and Company announced a definitive agreement to acquire Disarm Therapeutics, a privately-held biotechnology company creating a new class of disease-modifying therapeutics for…
Read More...

Y-mAbs Therapeutics, Inc. a late-stage clinical biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the…
Read More...

Nestlé announced the successful completion of its acquisition of Aimmune Therapeutics, Inc. Joining Nestlé Health Science (NHSc) as a stand-alone business unit called Aimmune…
Read More...

Dyno Therapeutics, a biotech company applying artificial intelligence (AI) to gene therapy, announced a collaboration and license agreement with Roche to apply Dyno’s CapsidMap platform…
Read More...

Boehringer Ingelheim and Oxford BioTherapeutics Ltd. (OBT) announced they are building on their successful partnership and are establishing a new alliance to discover additional…
Read More...

Today, the U.S. Food and Drug Administration approved Inmazeb (atoltivimab, maftivimab, and odesivimab-ebgn), a mixture of three monoclonal antibodies, as the first FDA-approved…
Read More...

Moderna, Inc., a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, announced the…
Read More...

Twist Bioscience Corporation, a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, and Neogene Therapeutics, Inc., a…
Read More...

HITGEN announces it has entered into a definitive agreement with Ligand Pharmaceuticals Inc. to acquire Vernalis (R&D) Limited, Cambridge, UK-based world leaders in fragment and…
Read More...